Clinical trialNCT05467891RecruitingPhase 2Interventional

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

SponsorOana DanciuEnrollment200HER2-negative Breast CancerHormone Receptor-positive Breast CancerLocoregional Recurrence

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Oana Danciu, MD
University of Illinois at Chicago
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama at Birmingham
Birmingham, Alabama, United States
Nusrat Jahan, MD
Recruiting
University of Arizona
Phoenix, Arizona, United States
Sima Ehsani
Recruiting
Georgetown University
Washington D.C., District of Columbia, United States
Katia Khoury, MD
Recruiting
Orlando Health Cancer Institute
Orlando, Florida, United States
Active, not recruiting
University of Illinois Cancer Center
Chicago, Illinois, United States
Oana Danciu, MD
Recruiting
Parkview Research Center
Fort Wayne, Indiana, United States
Melanie Clark, MD
Recruiting
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
Sneha Phadke, DO
Recruiting
Tufts Medical Center
Boston, Massachusetts, United States
Don Dizon, MD
Recruiting
University of Michigan Health System
Ann Arbor, Michigan, United States
Kathleen Kemmer, MD
Recruiting
University of Michigan Health-West
Wyoming, Michigan, United States
Terminated
University of Nebraska Medical Center
Omaha, Nebraska, United States
Amulya Yellala, MBBS
Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Coral Omene, MD
Recruiting
University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico, United States
Bernard Tawfik, MD
Recruiting
New York University Clinical Cancer Center
New York, New York, United States
Nancy Chan, MD
Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Ashley Davenport, MD
Recruiting
Providence Portland Medical Center
Portland, Oregon, United States
Alison Conlin, MD, MPH
Recruiting
Penn State Cancer Institute
Hershey, Pennsylvania, United States
Monali Vasekar, MD
Recruiting
Medical University of South Carolina
Charleston, South Carolina, United States
Abirami Sivapiragasam, MD
Recruiting
University of Virginia Health System
Charlottesville, Virginia, United States
Trish Millard, MD
Recruiting
Virginia Commonwealth University
Richmond, Virginia, United States
Masey Ross, MD, MS
Recruiting
University of Wisconsin
Madison, Wisconsin, United States
Kari Wisinski, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Anastrozole →Exemestane →Fulvestrant →Letrozole →Ribociclib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 13 Sept 2022
Primary completion: 15 Aug 2028
Completion: 15 Aug 2029
Last update posted: 16 Jul 2026
Registered enrollment: 200
Registry id: NCT05467891

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.